Pricing Log in Create free account
Saturday 7 November 2026 Export VSTM’s income statement to Excel — free account

Verastem, Inc.

VSTM Healthcare Biotechnology

Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.

Revenue
+113.6%
EPS
+45.2%
Free cash flow
+24.5%
Total debt
+52.9%

Quarter to September 2026, against a year earlier

8.43 0.95 −10.13%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
n/a
Altman Z
−6.34
Beneish M
10.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.80
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 7 2 1 — — 1 2 — 1 1 2 1
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 1,140.00
Revenue ttm 100.30
Net income ttm (178.90)
Free cash flow ttm (159.57)
Net debt Q (53.37)
Valuation
P/E 0.00
Forward P/E (5.99) (negative: loss-making)
Price / sales 8.51
Forward P/S Powerpack
Price / FCF 0.00
Price / book 84.49 (above 6: high)
Financial health
Current ratio Q 1.93 (at or above 1.5: strong)
Debt / equity Q 11.82 (above 2: weak)
Interest coverage Q (354.83)
Growth
Revenue growth Q +113.59% (above 0%: growing)
Operating income growth Q −84.76% (below 0%: shrinking)
EPS, this year +43.60% (at or above 15%: strong)
EPS, next year A +3.56%
Revenue, next year A +260.03% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +19.48% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 8.0×, against a ten-year median of 8.4×; over the ten years it ranged from −3.1× in 2023 to 224× in 2021.
P/S against its own 10 years 32.04%
10-year low 10-year high
P/B against its own 10 years 99.37%
10-year low 10-year high
EV/Sales against its own 10 years 49.39%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 137 89 205 173
Receivables — 0 9 —
Inventory — — 2 2
Other — — — —
144 95 223 199
2023 2024 2025 Q'26
Payables 7 4 12 20
ST’ Debt — — — 6
Other 0 — 5 —
26 31 72 103

Compound Annual Growth %

10y 5y 3y
Sales — 12.11% 146.94%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (5.66%) (13.08%) 6.47%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.46 Actual −0.35

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.51 −1.35 Miss by 0.84
Q4 FY25 −0.49 −0.50 Miss by 0.01
Q1 FY26 −0.46 −0.46 Met by 0.00
Q2 FY26 −0.46 −0.35 Beat by 0.11
Q3 FY26 −0.44 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.46) (0.35) (0.74) — —
’25 (0.96) (0.62) (1.35) (0.50) (3.02)
’24 (1.26) (0.31) (0.60) (1.32) (3.66)
’23 (0.96) (1.37) (0.75) (1.02) (3.96)
’22 (1.08) (1.44) (1.08) (0.96) (4.56)
’21 (1.08) (1.20) (1.56) (1.08) (4.92)
’20 (4.20) (1.68) 0.96 (1.44) (5.28)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 19 40 24 — —
’25 — 2 11 18 31
’24 — 10 — — 10
’22 3 — — — 3
’21 1 1 0 1 2
’20 5 4 79 1 89
’19 2 3 9 4 17
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (52) (44) (34) — —
’25 (39) (33) (36) (30) (138)
’24 (28) (28) (24) (25) (105)
’23 (20) (20) (17) (30) (86)
’22 (19) (13) (15) (17) (64)
’21 (19) (13) (11) (10) (54)
’20 (34) (23) 45 (22) (34)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (52) (44) (34) — —
’25 (39) (33) (44) (31) (147)
’24 (28) (28) (24) (25) (105)
’23 (20) (20) (17) (30) (86)
’22 (19) (13) (15) (17) (64)
’21 (20) (13) (11) (10) (54)
’20 (34) (23) 45 (22) (34)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 27 17 89 2 3 — 10 31 100 +2.1% 111 159 244 +99.2%
Gross margin, % 0.00 0.00 97.80 83.92 61.88 100.00 100.00 — 100.00 82.86 0.00 +82.9 pt
EBT (36) (68) (72) (149) (68) (71) (74) (87) (130) (209) (202) +21.4%
EBT margin, % 0.00 0.00 (271.11) (854.77) (76.29) (3,468.10) (2,843.30) 0.00 (1,304.52) (677.59) 0.00 (677.6) pt
Net income (36) (68) (72) (149) (68) (71) (74) (87) (131) (209) (179) +21.4%
Per share, $
Per share, $ Revenue 0.00 0.00 4.94 2.81 6.93 0.14 0.16 0.00 0.28 0.45 0.99 n/m
Earnings (11.88) (21.13) (13.44) (24.01) (5.28) (4.92) (4.56) (3.96) (3.66) (3.02) (1.85) (14.1%)
Cash flow (9.57) (17.91) (13.77) (22.30) (2.62) (3.68) (3.95) (3.92) (2.93) (1.98) (1.58) (16.0%)
Capex (0.01) 0.00 (4.33) 0.00 0.00 (0.01) 0.00 0.00 0.00 (0.14) 0.00 +30.4%
Free cash flow (9.58) (17.91) (18.10) (22.30) (2.63) (3.69) (3.95) (3.92) (2.93) (2.12) (1.58) (15.4%)
Book value 23.46 18.02 22.97 1.15 9.03 6.02 2.94 3.56 (0.81) 0.83 0.10 (31.1%)
Shares, m 3 3 5 6 13 15 16 22 36 69 92 +41.3%
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.0
P/S — — 0.00 5.72 3.69 174.17 22.28 — 14.05 13.08 8.51 33.3
P/B — — 1.76 13.92 2.83 4.08 1.71 — 0.00 9.35 84.49 4.8
EV/Sales — — 0.00 7.36 2.31 125.78 5.18 — 11.14 10.17 7.98 23.1
EV/FCF — — (1.17) (0.92) (6.11) (4.81) (0.30) — (1.40) (3.03) (5.01) (2.5)
Cash, $m
Cash, $m Operating cash flow (29) (57) (75) (139) (34) (54) (64) (86) (105) (138) (160) +18.7%
Capex 0 — (23) 0 0 0 — — 0 (10) 0 +84.4%
Free cash flow (30) (57) (98) (139) (34) (54) (64) (86) (105) (147) (160) +19.5%
Balance, $m
Balance, $m Working capital 70 71 216 55 128 87 71 117 64 151 96 +8.9%
Net debt (81) (72) (129) 28 (122) (100) (63) (97) (48) (129) (53) +5.3%
Shareholders’ equity 72 58 124 7 115 88 47 79 (29) 57 10 (2.6%)
Returns, %
Returns, % ROA (37.05) (78.19) (39.47) (70.67) (45.24) (54.14) (72.47) (71.39) (103.99) (120.39) (88.02) (83.3) pt
ROIC 0.00 0.00 0.00 (234.37) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (41.70) (104.33) (79.61) (226.98) (110.62) (70.21) (109.39) (166.79) (917.36) (1,480.15) 6,595.50 (1,438.4) pt
People
People Employees 32 69 169 135 48 48 57 73 78 102 — +13.7%
Revenue/emp, $m 0.00 0.00 0.16 0.13 1.84 0.04 0.05 0.00 0.13 0.30 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Verastem, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DRTS Alpha Tau Medical Ltd. $1.2B — (loss-making) — — n/m −30.42% (below 0%: shrinking) 0.00% 0.00% Compare
MNKD MannKind Corporation $1.2B — (loss-making) — (loss-making) +24.04% (above 0%: growing) n/m −267.69% (below 0%: shrinking) 0.00% (2.14%) Compare
AVLN Avalyn Pharma Inc. $1.2B — (loss-making) — — n/m — — 0.00% Compare
INBX Inhibrx Biosciences, Inc. $1.2B — (loss-making) — (loss-making) +992.44% (above 0%: growing) n/m +0.12% (above 0%: growing) 100.00% 0.00% Compare
VOR Vor Biopharma Inc. $1.2B — (loss-making) — — n/m −47.59% (below 0%: shrinking) 0.00% — Compare
VSTM Verastem, Inc. $1.1B — (loss-making) — (loss-making) +113.59% (above 0%: growing) n/m +24.50% (above 0%: growing) 0.00% (313.28%)
RAPP Rapport Therapeutics, Inc. $1.1B — (loss-making) — — n/m −64.75% (below 0%: shrinking) 100.00% 0.00% Compare
SGP SpyGlass Pharma, Inc. $1.1B — (loss-making) — — n/m −100.49% (below 0%: shrinking) — 0.00% Compare
SPTX Seaport Therapeutics, Inc $1.1B — (loss-making) — — n/m −43.81% (below 0%: shrinking) — 0.00% Compare
Median of peers $1.2B — — — — −47.59% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 9 April 2026

Ownership

Directors and executive officers, together 1.94%
Entities associated with RTW Investments, LP 9.99%
Entities associated with Deep Track Capital, LP. 9.99%
Entities associated with BlackRock, Inc. 5.41%
Entities associated with Balyasny Asset Management L.P. 5.33%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Verastem, Inc. (VSTM) Latest News

6 Nov

Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · GuruFocus.com

5 Nov

Impact 4 · · Business Wire

29 Oct

Impact 3 · · Simply Wall St.

28 Oct

Impact 4 · · Business Wire

23 Oct

Impact 4 · · Simply Wall St.

22 Oct

Impact 3 · · Business Wire

15 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Stocktwits
Impact 4 · · MT Newswires
Impact 4 · · clinicaltrialsarena.com

14 Oct

Impact 4 · · MarketBeat
Impact 4 · · biopharmadive.com
Impact 4 · · Stocktwits
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · MT Newswires

12 Oct

Impact 3 · · Zacks

2 Oct

Impact 4 · · Business Wire

28 Sep

Impact 4 · · Business Wire

24 Sep

Impact 4 · · Business Wire

21 Sep

Impact 4 · · MarketBeat

8 Sep

Impact 4 ·
Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 ·
Impact 3 · · MarketBeat

6 Aug

Impact 3 ·
stockrow.com/VSTM · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com